Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline

Aardvark Therapeutics faces a pending securities class action alleging it misled investors about ARD-101's safety, after reversible cardiac observations prompted a February 2026 pause of its Phase 3 HERO trial and the FDA imposed a full IND clinical hold on May 14. AARD shares fell more than 56% following the trial pause and another 32.1% after the FDA hold, materially impairing the clinical, regulatory and commercial outlook for its lead Prader-Willi syndrome therapy. Investors seeking lead-plaintiff status have until October 13, 2026.

Analysis

This is not a fresh fundamental catalyst: plaintiff-firm notices typically follow disclosed drawdowns and do not independently alter the FDA review path, cash runway, or probability of ARD-101 returning to clinic. The market-relevant issue is whether the company can define a dose/exposure threshold and satisfy the FDA with a revised cardiac-monitoring protocol; until then, AARD should trade as a financing-risk option rather than on the potential size of the PWS market. A prolonged hold raises the likelihood of discounted equity issuance, particularly if management cannot provide a credible remediation timeline in the next quarterly update.

The immediate read-through for direct PWS alternatives is modestly positive, with Soleno Therapeutics (SLNO) the clearest competitive beneficiary if AARD's delay removes a prospective entrant for 12-24 months. The larger second-order effect is on valuation: clinical-stage rare-disease companies with a single lead asset and pre-existing cardiovascular signals should carry a higher discount rate, while diversified rare-disease platforms should be relatively insulated. AARD could rally sharply on any FDA hold resolution, but resolution alone is insufficient—investors will need evidence that the revised protocol preserves commercially viable dosing and trial timelines.

Consensus may overemphasize litigation headlines; settlement exposure is generally immaterial relative to the value destruction already driven by clinical uncertainty. The underappreciated risk is that a seemingly remediable safety issue forces a lower dose or longer monitoring period, impairing efficacy differentiation and extending development enough to erode first-mover economics. Falsification of the bearish operating thesis would be FDA clearance coupled with a disclosed restart date, unchanged primary endpoint, adequate cash through a meaningful data readout, and no material dose limitation.

Key Decisions for Investors

• Do not initiate a directional AARD position solely on this legal notice; treat it as non-fundamental. Reassess only after the next company update provides FDA correspondence, cash runway, and a trial-restart timeline.
• Maintain a 6-18 month relative-value watch: long SLNO versus short AARD only after confirming AARD borrow availability and cost. The trade works if AARD's hold extends beyond one additional quarter; exit the short leg on FDA clearance with a funded restart plan.
• For existing AARD longs, reduce exposure into any headline-driven rebound unless it is supported by a defined regulatory remedy. A hold-resolution announcement without dosing, protocol, and financing detail is a potential liquidity-sale opportunity rather than thesis confirmation.
• Set alerts for: FDA clinical-hold release, revised Phase 3 protocol, quarterly cash burn/runway, and any equity financing. These are the 1-3 month catalysts that matter; the October lead-plaintiff deadline is unlikely to be a tradable event.